Oncology

Top Story

Reduced Nexavar dosage yields cost benefits, does not affect OS in HCC

September 14, 2017

Patients with hepatocellular carcinoma who started Nexavar therapy at reduced dosages had a lower total cumulative pill cost and were less likely to discontinue due to adverse effects, according to recently published data. Additionally, lower starting doses did not affect overall survival.

“Prior small retrospective studies have suggested that using a [Nexavar] dosage escalation strategy might be beneficial, or at least not harmful, to patients with HCC,” Kim A. Reiss, MD, from the Perelman Center for Advanced Medicine, Philadelphia, and colleagues wrote. “This retrospective analysis of nearly 5,000 patients with HCC who were prescribed [Nexavar] suggests that starting patients on a reduced starting dose does not reduce OS after propensity score matching for multiple clinical variables.”

In the Journals

Gallbladder cancer linked to mold toxin

September 11, 2017
Dietary exposure to aflatoxin, or toxins produced by fungi affecting certain crops, may increase the risk for gallbladder cancer, according to new research. “If…
In the Journals

HCC rates vary by race in US, highest among Asian-Pacific Islanders

September 5, 2017
Among U.S. veterans with hepatitis B, researchers found that the risk for hepatocellular carcinoma was higher among Asian-Pacific Islanders than Caucasians and…
In the Journals

Higher FIB-4 index in patients with HBV linked to increased HCC risk

August 31, 2017
In a cohort of patients with chronic hepatitis B without cirrhosis, the risk for hepatocellular carcinoma was significantly higher among those with a FIB-4 index over…
More Headlines »
Advertisement
Advertisement